Acrivon Therapeutics, Inc. (ACRV) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 platform. The company is an emerging growth company and a smaller reporting company. As of August 7, 2026, there were 42,853,362 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(17.96) million | $(37.01) million | $(40.69) million |
| Net Loss Per Share (Basic/Diluted) | $(0.43) | $(0.92) | $(1.06) |
| Operating Expenses | $18.67 million | $38.57 million | $44.31 million |
| Cash, Cash Equivalents & Investments | $90.0 million (as of June 30, 2026) | ||
| Accumulated Deficit | $(311.9) million (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(35.4) million (YTD 2026) |
Material Changes vs. Prior Period
- Reduced Operating Loss: Net loss for the six months ended June 30, 2026, decreased by $3.7 million compared to the same period in 2025, driven primarily by lower operating expenses.
- Expense Reductions:
- R&D Expenses: Decreased by $2.6 million YTD, primarily due to a $1.9 million reduction in ACR-368 clinical trial costs (non-recurring milestones in 2025) and lower costs for ACR-2316 and preclinical discovery.
- G&A Expenses: Decreased by $3.2 million YTD, largely attributed to a $2.8 million reduction in employee-related expenses, including stock-based compensation.
- Lower Interest Income: Total other income decreased by $2.1 million YTD due to lower interest income and accretion on investments.
- Capital Raise: In April 2026, the company raised approximately $7.3 million through an "at-the-market" (ATM) offering, selling 4,054,954 shares at $1.80 per share.
Outlook, Guidance, and Risks
- Liquidity Runway: Management believes existing cash, cash equivalents, and investments of $90.0 million are sufficient to fund operations into the fourth quarter of 2027.
- Clinical Pipeline Updates:
- ACR-368 (Prexasertib): Phase 2b trial in endometrial cancer (EC) showed an Objective Response Rate (ORR) of 39% in biomarker-positive patients and 52% in pooled serous EC patients with ≤2 prior lines of therapy. New arms (3 and 4) are enrolling "all-comer" serous EC patients, with or without ultra-low dose gemcitabine sensitization. Interim data is expected in H2 2026.
- ACR-2316: Phase 1/2 trial has advanced to the randomized dose expansion stage, evaluating the drug in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- Risks: The company has no approved products and has never generated revenue. Continued losses are expected. Future funding is required to sustain operations; failure to raise capital could force delays in development. Clinical trial outcomes remain uncertain.
Key Investor Verification Points
- Cash Burn Rate: Verify the sustainability of the $35.4 million operating cash burn over the next 18 months against the $90 million liquidity position.
- ACR-368 Data Readout: Monitor the timing and results of the H2 2026 interim analysis for the "all-comer" arms in the Phase 2b endometrial cancer trial.
- Capital Requirements: Assess the likelihood and terms of future equity or debt financing needed to extend the runway beyond late 2027.
- Stock-Based Compensation: Note the significant reduction in stock-based compensation expense ($3.3 million decrease YTD) and its impact on future expense projections as new grants vest.
- Intellectual Property: Confirm the status of the license agreement with Eli Lilly, specifically regarding the expiration of the right of first negotiation (ROFN) which occurred in July 2025, granting Acrivon unencumbered rights for strategic partnerships.